Mechanism of Action
MOTS-c operates primarily through the Folate-AICAR-AMPK pathway and nuclear stress-response signaling.
AMPK Activation via Folate-AICAR Pathway
MOTS-c inhibits the folate cycle, specifically the enzyme MTHFD1 (methylenetetrahydrofolate dehydrogenase), blocking the conversion of formyl-THF to THF. This leads to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a natural AMPK activator. AMPK activation triggers glucose uptake, fatty acid oxidation, and mitochondrial biogenesis, the core of MOTS-c's metabolic effects.[1]Nuclear Stress Response Signaling
Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it binds stress-response transcription factors NRF2 and ATF1/ATF7. This nuclear activity regulates gene expression for antioxidant defense, metabolic adaptation, and cellular stress tolerance, functions distinct from its cytoplasmic AMPK pathway.[2]Exercise-Induced Endogenous Production
Skeletal muscle produces MOTS-c endogenously during exercise, with a documented 11.9-fold increase in muscle MOTS-c protein expression following training. This identifies MOTS-c as a potential mediator of exercise benefits, and explains why exogenous MOTS-c enhances the exercise response.[3]Research Overview
Insulin Sensitivity & Metabolic Health
Most StudiedMOTS-c improves insulin sensitivity by ~30% in animal studies through AMPK activation. It enhances glucose uptake in skeletal muscle, reduces hepatic glucose production, and improves glucose tolerance in diet-induced insulin resistance models. Clinical trials in gestational diabetes showed significantly lower endogenous MOTS-c levels in affected patients versus controls.[1]
Exercise Performance
Strong EvidenceSingle-dose MOTS-c (15 mg/kg i.v.) improved running time by 12% and distance by 15% in untrained mice. Chronic administration enhanced performance across young, middle-aged, and aged animals, suggesting MOTS-c counteracts age-related physical decline. Endogenous MOTS-c increases 11.9-fold in muscle with exercise training.[3]
Anti-aging & Longevity
EmergingMOTS-c levels decline with chronological aging. In centenarian cohort studies, specific MOTS-c variants are enriched, suggesting positive selection for higher MOTS-c activity in long-lived individuals. Animal models show extended healthspan with chronic MOTS-c supplementation.[4]
Obesity Prevention
Moderate EvidenceMOTS-c prevents weight gain and fat accumulation in high-fat diet mouse models despite identical caloric intake. The mechanism involves AMPK-driven upregulation of fatty acid oxidation and enhanced thermogenesis through mitochondrial uncoupling.[1]
Calculate your MOTS-c dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic health | 5–10 mg | Once daily | Subcutaneous |
| Exercise performance | 10–15 mg | Pre-workout | Subcutaneous |
| Anti-aging protocol | 15 mg | 3× weekly | Subcutaneous |
| Conservative start | 5 mg | Once daily | Subcutaneous |
Morning dosing before exercise is optimal, exercise amplifies endogenous MOTS-c production, and exogenous MOTS-c synergizes with this effect. AMPK activation occurs within 30 minutes of administration. Fasted administration may enhance metabolic effects.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
MOTS-c demonstrates a favorable safety profile in preclinical research. No significant organ toxicity has been identified in rodent studies at research doses.
WADA Status: MOTS-c is prohibited by WADA as an AMPK activator and metabolic modulator. Competitive athletes subject to testing must not use this compound.
Glycemic monitoring: Due to AMPK-mediated glucose uptake, monitor blood glucose when co-administering with diabetes medications or insulin sensitizers. Hypoglycemia risk exists particularly in fasted protocols.
No FDA approval: Not approved for any human therapeutic use. Human clinical data is limited to observational studies. All interventional human use is experimental.
References
- [1]Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-454.
- [2]Kim SJ, et al. "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress." Cell Metab. 2018;28(3):516-524.e7.
- [3]Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nat Commun. 2021;12(1):470.
- [4]Zarse K, et al. "Mitochondria-derived peptides MOTS-c and humanin, two related but distinct regulators of aging and metabolism." Ageing Res Rev. 2022;81:101728.